Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Mutant isoforms of the KIT or PDGF receptors expressed by gastrointestinal stromal tumors (GISTs) are considered the therapeutic targets for STI571 (imatinib mesylate; Gleevec), a specific inhibitor of these tyrosine kinase receptors.Case reports of clinical efficacy of Gleevec in GISTs lacking the typical receptor mutations prompted a search for an alternate mode of action.Here we show that Gleevec can act on host DCs to promote NK cell activation.DC-mediated NK cell activation was triggered in vitro and in vivo by treatment of DCs with Gleevec as well as by a loss-of-function mutation of KIT.Therefore, tumors that are refractory to the antiproliferative effects of Gleevec in vitro responded to Gleevec in vivo in an NK cell-dependent manner.Longitudinal studies of Gleevec-treated GIST patients revealed a therapy-induced increase in IFN-γ production by NK cells, correlating with an enhanced antitumor response.These data point to a novel mode of antitumor action for Gleevec.Nonstandard abbreviations used: bi-injection daily (bid); bone marrow-derived DC (BM-DC); break point cluster region/Abelson leukemia virus (BCR/ABL); chronic myelogenous leukemia (CML); c-kit loss-of-function mutation (W/Wv); fms-like tyrosine 3 kinase ligand (FL); gastrointestinal stromal tumor (GIST); progression-free survival (PFS); stem cell factor (SCF); transporter associated with antigen processing (TAP).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Imatinib was arguably the first targeted anticancer agent to demonstrate immunostimulatory effects that are directly linked to NK-cell activation”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Borg et al., 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389 · cited 1×
“Gleevec administration results in objective (partial or complete) response or stabilization in about 80% of GIST patients (6).”
BackgroundSelf-citationEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · cited 1×
“The renaissance of interest in NK cells in tumor immunosurveillance can be attributed to the discovery of stressinduced ligands for receptors that activate NK cells (23–25) and to the relevance of interactions between MHC class I molecules and killer inhibitory receptors in mismatched hematopoietic transplants, which…”
BackgroundActivation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301 · cited 1×
“Somatic gain-of-function mutations of the c-kit protooncogene are found in 85% of GISTs (1), and recently, mutations of the PDGFRα chain were reported in 35% of the GISTs lacking the KIT mutations (2).”
BackgroundKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299 · cited 4×
“GISTs harboring an exon 11 mutation (76% of GISTs) exhibit the highest objective response rate and the longest time to progression (7).”
BackgroundTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592 · cited 1×
“Notably, in 50% of GIST-bearing patients, a fraction of circulating NK cells showed a downregulation of NKG2D expression at diagnosis (data not shown), which suggests that GISTs secrete soluble NKG2D ligands that might downregulate NKG2D expression on blood NK cells, similarly to the downregulation seen on T cells (30…”
BackgroundCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., & McKenna, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1953 · Cited by 1,115 · cited 6×
“Since FL is known to amplify DCs, (14) and since mature DCs have the unique capacity to promote NK cell effector functions including IFN-γ secretion and antitumor effects in vivo (10, 15), we hypothesized that Gleevec could confer an NK cell stimulatory capacity to host DCs. Gleevec enhanced IFN-γ production by NK cel…”
BackgroundInfluentialRae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,060
Research works printed but not linked: 1
- Van Glabbeke, M.M., et al. 2003. Prognostic factors of toxicity and efficacy in patients with gastro-intes- tinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc. Am. Soc. Clin. Oncol. 22:3286.
Cited by
Items 301–302 of 302
Targeting KIT and PDGFRA mutations in advanced GIST: current and future clinical implications
Costa, A., Astolfi, A., Gozzellino, L., Nigro, M. C., Pantaleo, M. A., & Nannini, M. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2746618
Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas
Alosi, J. A., Baldwin, S. W., Oxenberg, J. C., & Skitzki, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_17
Metadata
- Authors
- Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., Cesne, A. L., Chung-Scott, V., Lazar, V., Tchou, I., Crépineau, F., Lemoine, F., Bernard, J., Fletcher, J. A., Turhan, A., Blay, J.-Y., Spatz, A., Emile, J.-F., Heinrich, M. C., Mécheri, S., Tursz, T., & Zitvogel, L.
- Affiliations
- Inserm (FR)
- National Cancer Centre Japan (JP)
- Vrije Universiteit Brussel (BE)
- Institut Gustave Roussy (FR)
- Institut Jean Godinot (FR)
- Harvard University (US)
- Hospices Civils de Lyon (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Oregon Health & Science University (US)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-08-01
- Volume
- 114
- Issue
- 3
- Pages
- 379-388
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC489961
- OpenAlex
- W2161785083
- Cited by
- 302
- References
- 35
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 11 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 4 · 2017: 11 · 2016: 14 · 2015: 19 · 2014: 16 · 2013: 24 · 2012: 19
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Institut National de la Santé et de la Recherche Médicale
- Hospices Civils de Lyon
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, NK cell activation, dendritic cells, interferon-gamma, antitumor immunity, PDGF receptor, stem cell factor
- MeSH terms
- Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Dendritic Cells, Enzyme Inhibitors, Female, Gastrointestinal Neoplasms, Humans, Interferon-gamma, Killer Cells, Natural, Leukocytes, Mononuclear, Longitudinal Studies, Mice, Inbred C57BL, Mutation, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Gene Expression Regulation, Neoplastic, Case-Control Studies, Mice, SCID, Stromal Cells, Receptors, Platelet-Derived Growth Factor, Mice, Knockout, Neutrophil Activation, Coculture Techniques, Proto-Oncogene Proteins c-kit, Receptor Protein-Tyrosine Kinases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.